Market capitalization | $6.50m |
Enterprise Value | $5.91m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.15 |
P/S ratio (TTM) P/S ratio | 1.26 |
P/B ratio (TTM) P/B ratio | negative |
Turnover (TTM) Turnover | $5.16m |
EBIT (operating result TTM) EBIT | $-15.64m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Yumanity Therapeutics Inc:
1 Analyst has issued a forecast Yumanity Therapeutics Inc:
Dec '23 |
+/-
%
|
||
Turnover | 5.44 5.44 |
179%
179%
|
|
Gross income | 5.43 5.43 |
345%
345%
|
|
EBITDA | -16 -16 |
28%
28%
|
EBIT (operating result) EBIT | -16 -16 |
31%
31%
|
Net profit | -14 -14 |
78%
78%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA.
Head office | United States |
CEO | Shawn Iadonato |
Employees | 11 |
Founded | 2008 |
Website | www.kinetabio.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.